Risk Factors and Association of CMV Reactivation with Clinical Outcomes in ICU Patients

Merck Sharp and Dohme Corp. (PI: Limaye)
01/01/2018-12/31/2018

This project will characterize the specific CMV reactivation parameters associated with key clinical outcomes for a future phase 3 study. As well as allow investigators to identify specific baseline risk factors that are predictive of the CMV reactivation parameters linked with key clinical outcomes.

Aim 1. Characterize the specific CMV reactivation parameters associated with key clinical outcomes for a future phase 3 study.

Aim 2. Identify specific baseline risk factors that are predictive of the CMV reactivation parameters linked with key clinical outcomes.